Nancy Marie Allen LaPointe, PharmD

Adjunct Associate Professor in the Department of Medicine
Member in the Duke Clinical Research Institute
Campus mail Remote, Raleigh, NC 27607
Email address nancy.allenlapointe@duke.edu

Dr. Allen LaPointe is an Adjunct Associate Professor in Medicine and Faculty Fellow at the Duke-Margolis Center for Health Policy at Duke University.  She is a researcher and cardiovascular clinical pharmacist with extensive experience in health outcomes and health services research, evidence synthesis, and the protection of human research subjects.  Her clinical and research work have been focused on patient safety, predominately in patients with cardiovascular disease.  This includes work in reducing medication errors, improving medication adherence, safely and effectively translating evidence into clinical practice, comparing safety and effectiveness of therapeutics, evaluating risk communication and mitigation strategies, and exploring the interface between health policy and patient safety.  
 

Education and Training

  • M.H.S., Duke University, 2013
  • Pharm.D., Purdue University, 1988

Publications

Kramer, Judith M., Donald Fetterolf, John P. Charde, Richard Snyder, Daniel Checkman, Elizabeth DeLong, Nancy Allen LaPointe, Barbara Hoffman, Rhonda L. Arrington, and Eric Peterson. “838-4 National evaluation of long-term adherence to beta-blocker therapy after acute myocardial infarction in patients with commercial health insurance.” In Journal of the American College of Cardiology, 43:A415–16. Elsevier BV, 2004. https://doi.org/10.1016/s0735-1097(04)91753-6.

Full Text

Al-Khatib, Sana M., Nancy M. Allen LaPointe, Judith M. Kramer, Anita Y. Chen, Bradley G. Hammill, Liz DeLong, and Robert M. Califf. “1096-71 A national survey of health care practitioners' knowledge of the QT interval.” In Journal of the American College of Cardiology, 43:A408–A408. Elsevier BV, 2004. https://doi.org/10.1016/s0735-1097(04)91724-x.

Full Text

Cowper, Patricia A., Elizabeth R. DeLong, David J. Whellan, Nancy M. Allen LaPointe, and Robert M. Califf. “Economic effects of beta-blocker therapy in patients with heart failure.” Am J Med 116, no. 2 (January 15, 2004): 104–11. https://doi.org/10.1016/j.amjmed.2003.07.016.

PMID
14715324
Full Text

Newby, L Kristin, Manjushri V. Bhapkar, Harvey D. White, David J. Moliterno, Nancy M Allen LaPointe, David E. Kandzari, Freek W. A. Verheugt, et al. “Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.” J Thromb Thrombolysis 16, no. 3 (December 2003): 119–28. https://doi.org/10.1023/B:THRO.0000024050.78728.35.

PMID
15087598
Full Text

Allen LaPointe, Nancy M., Anita Chen, Bradley Hammill, Elizabeth DeLong, Judith M. Kramer, and Robert M. Califf. “Evaluation of the dofetilide risk-management program.” Am Heart J 146, no. 5 (November 2003): 894–901. https://doi.org/10.1016/S0002-8703(03)00409-5.

PMID
14597941
Full Text

LaPointe, Nancy M Allen, Carol A. Pamer, and Judith M. Kramer. “New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.” Pharmacotherapy 23, no. 10 (October 2003): 1316–21. https://doi.org/10.1592/phco.23.12.1316.32703.

PMID
14594348
Full Text

Al-Khatib, Sana M., Nancy M Allen LaPointe, Judith M. Kramer, and Robert M. Califf. “What clinicians should know about the QT interval.” Jama 289, no. 16 (April 23, 2003): 2120–27. https://doi.org/10.1001/jama.289.16.2120.

PMID
12709470
Full Text

LaPointe, Nancy M Allen, Sana M. Al-Khatib, Judith M. Kramer, and Robert M. Califf. “Knowledge deficits related to the QT interval could affect patient safety.” Ann Noninvasive Electrocardiol 8, no. 2 (April 2003): 157–60. https://doi.org/10.1046/j.1542-474x.2003.08211.x.

PMID
12848798
Full Text

Pages